Drug-resistant TB is a major global public health problem that threatens the significant progress made in TB care and prevention in recent decades.
In most cases, tuberculosis is treatable and curable. However, standard TB treatment requires up to six months of drugs that can cause nausea, vomiting and stomach pain. The duration and side effects drive some people to abandon their treatment, which can lead to drug resistance -when tuberculosis bacteria is resistant to at least one of the main TB drugs.
Globally, only half of multidrugresistant tuberculosis (MDR-TB) patients who initiate treatment are successfully treated, mostly due to high mortality and falling out of the treatment programs. Outcomes for individuals with extensively drugresistant tuberculosis (XDR-TB) are worse -as reported by WHO in 2017, only 30% of patients were successfully treated.
As antimicrobial resistance goes, tuberculosis is an enormous problem.
Deaths from drug-resistant TB now account for about one-third of all antimicrobial resistance deaths worldwide. Treating drug-resistant TB is costlier and can take three to four times as long -not all people survive. The Challenge
After three years of treatment, Aftab Ansari was finally cured of drug-resistant TB, but the disease robbed him of his livelihood and drove him into debt. With 27% of global cases, TB will cost India more than US$250 billion through 2030, according to one study.
TB continues to be a major public health issue worldwide. In Anastasia's home country of Belarus, nearly 38% of new TB cases are MDR-TB. By comparison, the global average is just over 4%. Anastasia will beat MDR-TB, and the Global Fund continues to support countries to improve prevention, diagnosis and treatment -to meet the target of ending the TB epidemic by 2030.
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FINDING MISSING CASES
Despite treatment success and lower mortality rates, "missing" people with TB -people who are not diagnosed, treated or reported -are a major challenge in the fight against TB, and contribute to the growing problem of drug-resistant TB. Worldwide, 36% of the 10 million people who get sick with TB were missed in 2017.
Reuben Kimweli tracks down cases of tuberculosis that go undiagnosed, untreated or unreported in his community in Kibera, Kenya. Working for a program run by Amref Health Africa, he is one of thousands of community health workers on the frontlines of the global effort to reduce emerging drug resistance. By the end of 2018, the 13 countries notified almost 4.6 million TB patients compared to 3.7 million 2015. If these notification trends continue, the 13 countries will be on track to achieve the target of finding 1.5 million additional people with TB by the end of 2019.
Diagnostic Technology
GeneXpert technology has transformed the way the world diagnoses drug-resistant tuberculosis. It has allowed screening of thousands of TB cases around the world, quickly and efficiently. The Global Fund partnership is investing heavily in expansion of this technology but the need continues to be bigger than the resources available. There is also need to expand the testing for resistance to second line medications. This is important in helping identify patients with drug-resistant TB to initiate them on more effective and less toxic treatment regimens as recommended by WHO.
New Drugs
The Global Fund is supporting countries to introduce bedaquiline and delamanid, two groundbreaking new drugs for the treatment of drug-resistant TB. As bedaquiline is currently available free through a USAID donation from Janssen Pharmaceuticals, countries have been able to reprogram Global Fund investments that were originally set aside for treatment of the disease, freeing up funds to support additional MDR-TB interventions. The new drugs have fewer side effects and are more effective, increasing the chances that people will stay on the treatment and be cured.
Community Involvement TB patients frequently stop treatment before it is completed, leading to drugresistant TB. The Global Fund invests in community systems, supporting volunteers to raise awareness, fight stigma and improve access to TB health services, treatment and care. By supporting community health workers who knock on doors and support community members through treatment, the Global Fund is working with local health workers across the world to prevent people from getting drug-resistant TB and to treat those already affected by the disease. 
Results in 2017 in

Stronger Systems for Health
In the end, the response to drugresistant TB relies heavily on strong and functional health systems. One-quarter of the Global Fund's investments support building resilient and sustainable systems for health, including training for health workers, improved facilities and access, and strengthened information systems and supply chain management.
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About the Global Fund
The Global Fund is a 21st-century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. As a partnership between governments, civil society, the private sector and people affected by the diseases, the Global Fund mobilizes and invests nearly US$4 billion a year to support programs run by local experts in more than 100 countries. By challenging barriers and embracing innovative approaches, we are working together to better serve people affected by the diseases.
In Zaatari camp in the Jordanian desert, the Global Fund is supporting the provision of essential TB prevention, diagnosis and treatment services to Syrian refugees. What started as a temporary shelter for people fleeing the conflict in Syria has grown into a city of about 80,000 people. The people here benefit from TB services such as screening upon arrival, medical care and referral services, as well as health education.
